To amend the Federal Food, Drug, and Cosmetic Act to encourage innovation and increase and protect consumer access with respect to dietary supplements by clarifying the regulatory framework governing drug preclusion, and for other purposes.
Summary
HR10336 clarifies FDA's drug preclusion authority over dietary supplements, reducing regulatory risk for supplement manufacturers. The bill is early-stage but signals a pro-industry shift that benefits pure-play supplement companies. No funding is authorized; the impact is regulatory certainty.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10336 clarifies FDA's drug preclusion rule, reducing regulatory risk for dietary supplement manufacturers.
- 2.The bill is early-stage (referred to committee) with no cosponsors; immediate market impact is low but structural tailwind is real.
- 3.Pure-play supplement companies ($NUS, $USNA, $HLF, $NATR) are primary beneficiaries; pharmaceutical companies are neutral.
- 4.No funding is authorized; the benefit is entirely regulatory certainty, which can improve revenue visibility and R&D investment.
Market Implications
The bill is a positive signal for the dietary supplement industry, reducing the likelihood of FDA enforcement actions that could disrupt product lines. For $NUS, $USNA, $HLF, and $NATR, the primary effect is improved regulatory clarity and lower compliance costs. No price data is available, but historically, supplement stocks trade at a premium when regulatory uncertainty recedes. The lack of cosponsors and early committee stage limit near-term catalysts, but the bill introduces a favorable pivot in supplement policy.
Full Analysis
On September 10, 2026, Representative Diana Harshbarger (R-TN) introduced HR10336, a bill to amend the Federal Food, Drug, and Cosmetic Act to clarify when a dietary supplement ingredient is precluded by drug approval. The bill is referred to the House Committee on Energy and Commerce, an early legislative stage with no cosponsors. It does not authorize funding; its mechanism is regulatory clarification.
The bill targets the 'drug preclusion' provision in FD&C Section 201(ff)(3)(B), which currently bars supplement ingredients that have been approved as drugs or authorized for clinical investigation. HR10336 sets clearer standards for when a supplement is not precluded—essentially protecting supplements that meet safety and labeling requirements even if the same ingredient exists in a drug. This reduces FDA's discretion to retroactively ban supplement ingredients, a key risk for the industry.
For the supplement sector, this is a structural tailwind. Pure-play supplement companies—Nu Skin ($NUS), USANA ($USNA), Herbalife ($HLF), and Nature's Sunshine ($NATR)—face reduced regulatory overhangs, lower compliance costs, and increased ability to innovate with ingredients. The bill improves earnings visibility by removing a major legal uncertainty that has historically led to product withdrawals and revenue loss. Pharmaceutical companies ($JNJ, $LLY) are neutral; the bill does not affect drug exclusivity or marketing rights.
The legislative path is long: it must pass the House Energy and Commerce Committee, the full House, the Senate, and be signed by The President. Given the early stage and single sponsor, near-term market impact is limited. However, increased legislative attention to supplement regulation suggests a favorable environment for the industry. Investors should monitor committee markup and potential companion bills.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Limited confirming evidence — causal thesis exists but few external signals
What the bill does
Clarification of drug preclusion rule under FD&C Act to prevent FDA from automatically excluding dietary supplement ingredients based on prior drug approval, provided the supplement meets safety and labeling standards.
Who must act
FDA Center for Food Safety and Applied Nutrition (CFSAN) and dietary supplement manufacturers
What happens
Reduced regulatory risk for supplement product launches and reformulations; FDA must follow clearer standards when deciding whether a supplement is precluded, decreasing uncertainty and potential enforcement actions.
Stock impact
Nu Skin Enterprises ($NUS) derives over 90% of revenue from dietary supplements and personal care products. This bill lowers the probability of FDA adverse actions that could disrupt product lines, protecting an estimated $1.8B in annual supplement revenue from regulatory threats.
What the bill does
Same as above: clarification of drug preclusion rule.
Who must act
FDA and dietary supplement manufacturers
What happens
Same as above: reduced regulatory risk for product launches and renewals.
Stock impact
USANA Health Sciences ($USNA) generates virtually all revenue from nutritional supplements. The bill removes a key overhang that could limit ingredient innovation and product line expansion, protecting an estimated $1B+ supplement business from potential FDA preclusion actions.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Dietary Supplements Access Act
Dietary Supplements Access Act
Dietary Supplement Listing Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
FURTHER MODIFYING THE SCOPE OF PRODUCTS OF CANADA SUBJECT TO THE ADDITIONAL DUTIES IMPOSED TO OFFSET CANADIAN DISCRIMINATION AGAINST THE COMMERCE OF THE UNITED STATES WITH RESPECT TO MOTOR VEHICLES
This proclamation modifies the list of Canadian products subject to a 50% additional ad valorem duty imposed under Section 338 of the Tariff Act of 1930, removing some products from the duty and adding others, effective October 30, 2026. The action is part of an ongoing dispute over Canada's motor vehicle tariff scheme and is intended to offset discrimination against U.S. commerce. The President directs implementation through the Harmonized Tariff Schedule and authorizes U.S. Customs and Border Protection to issue rules.
DECREASING HOUSING COSTS FOR THE AMERICAN PEOPLE
This executive order directs the Federal Housing Finance Agency to create pilot programs for automatic cancellation of mortgage insurance when borrowers have sufficient equity, and to expand a title insurance pilot to reduce costs for refinancing. It establishes a task force to promote manufactured housing by standardizing permits and reducing regulatory barriers. It also orders the Departments of Agriculture and Veterans Affairs to reduce interest rates on direct home loans.
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →